financetom
Business
financetom
/
Business
/
Urban Outfitters Can Mitigate Tariff Headwinds, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Urban Outfitters Can Mitigate Tariff Headwinds, UBS Says
Sep 2, 2025 12:22 PM

03:12 PM EDT, 09/02/2025 (MT Newswires) -- Urban Outfitters ( URBN ) is positioned to mitigate more of the tariff headwinds than previously expected by shifting the country of origin for goods, negotiating with vendors, adjusting transportation modes, and raising prices selectively, UBS Securities said.

The company reported fiscal Q2 net income of $1.58 per diluted share, compared with $1.24 a year earlier and ahead of the $1.48 expected by analysts. Net sales for the period ended July 31 rose to $1.50 billion from $1.35 billion a year earlier, topping the $1.48 billion consensus.

The brokerage said in a Monday note that the company's fiscal Q2 beat was helped by lower markdowns and rent leverage.

The firm raised its gross margin estimates for Q3 and Q4 by 20 and 80 basis points, respectively, and lifted Q3 sales and adjusted EPS forecasts to $1.46 billion and $1.21, respectively.

For 2025, UBS now models sales of $6.04 billion and adjusted EPS of $5.15, while its longer-term EPS forecasts for 2026 and 2027 were each increased by $0.05 on a stronger margin outlook.

The brokerage also pointed to mid-single digit comparable sales growth modeled for Anthropologie, Free People, and Urban Outfitters brands.

The firm said it continues to expect the stock to perform in line with peers over the next 12 months.

UBS raised its price target to $79 from $78 and reiterated its neutral rating on the company's stock.

Price: 66.75, Change: -0.32, Percent Change: -0.47

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Zscaler Plans $1.5 Billion Notes Offering
Zscaler Plans $1.5 Billion Notes Offering
Jun 30, 2025
07:38 AM EDT, 06/30/2025 (MT Newswires) -- Zscaler ( ZS ) said Monday it plans to offer $1.5 billion worth of convertible senior notes due 2028 in a private offering. The information security company said it will grant the initial purchasers of the notes a 13-day option to purchase up to an additional $225 million worth of the notes. Net...
W&T Offshore Says Court Rules Against $100 Million Collateral Demand by Surety Companies
W&T Offshore Says Court Rules Against $100 Million Collateral Demand by Surety Companies
Jun 30, 2025
07:41 AM EDT, 06/30/2025 (MT Newswires) -- W&T Offshore ( WTI ) said Monday that US Magistrate Judge Dena Palermo recommended denying motions by two surety companies for a preliminary injunction asking the company to post collateral of more than $100 million. The court found that the surety companies failed to demonstrate they would suffer irreparable harm if their cash...
Moderna Reports Positive Data From Phase 3 Study of mRNA-1010 Seasonal Influenza Vaccine Candidate
Moderna Reports Positive Data From Phase 3 Study of mRNA-1010 Seasonal Influenza Vaccine Candidate
Jun 30, 2025
07:38 AM EDT, 06/30/2025 (MT Newswires) -- Moderna ( MRNA ) said Monday that results from a phase 3 study demonstrated the superior relative vaccine efficacy of its mRNA-1010 seasonal influenza vaccine candidate compared with a licensed standard-dose seasonal influenza vaccine in adults aged at least 50 years old. The company said mRNA-1010 had a relative vaccine efficacy of 26.6%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved